Abstract
No public abstract is available from the verified source records.
Enrica Manzato, Michele Puppi, Simona Barbato, Ilaria Sacchetti, Simone Masci, Roberta Restuccia, Stefano Ghibellini, Lucia Pantani, Katia Mancuso, Ilaria Rizzello, Marco Talarico, Gloria Cocchetto, Chiara Terreo, Miriam Iezza, Michele Cavo, Elena Zamagni, Paola Tacchetti
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Teclistamab in relapsed or refractory multiple myeloma
10.1056/nejmoa2203478 · 2022
Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma
10.1056/nejmoa2204591 · 2022
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
10.1038/s41591-023-02528-9 · 2023
Linvoseltamab for treatment of relapsed/refractory multiple myeloma
10.1200/jco.24.01008 · 2024
EHA–EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
10.1038/s41571-025-01041-x · 2025
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
10.1016/s1470-2045(24)00043-3 · 2024
European expert panel consensus on outpatient administration of teclistamab and talquetamab in patients with multiple myeloma: feasibility, key considerations, and future directions
10.1111/ejh.14444 · 2025
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
10.3389/fonc.2025.1630146 · 2025
P-286 Impact of hypogammaglobulinemia and immunoglobulin replacement therapy on infection rate in patients with RRMM treated with elranatamab: post-hoc analysis from MagnetisMM-3
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/s2152-2650(23)01904-3 · 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
10.1182/bloodadvances.2023011658 · 2024
Optec: a phase 2 study to evaluate outpatient step-up administration of teclistamab in patients with relapsed/refractory multiple myeloma (RRMM): updated results
10.1182/blood-2024-207295 · 2024
Unresolved referenced work
Kept as external metadata until matched
An outpatient model for teclistamab step-up dosing administration – initial experiences at FOX chase cancer center BMT program [abstract]
10.1097/01.hs9.0000970664.60500.7f · 2023
Real-world safety outcomes and healthcare resource utilization (HCRU) during outpatient, inpatient, and hybrid step-up dosing (SUD) of teclistamab (Tec) and talquetamab (Tal): a chart review study
10.1016/s2152-2650(25)03524-4 · 2025
Prophylactic dexamethasone (dex) with outpatient step-up dosing (SUD) of bispecific antibodies (BsAb) in multiple myeloma (MM) v. standard of care (SOC) inpatient observation
10.1016/s2152-2650(25)03562-1 · 2025
Feasibility and safety of outpatient model for administration of bispecific antibodies: proceedings from an International Myeloma Society 21st Annual Meeting oral abstract
10.1016/j.clml.2025.04.002 · 2025
Real-world safety and health care resource utilization of teclistamab under an outpatient model for step-up dosing administration
10.1200/op-24-00489 · 2025
Bispecific outpatient step-up dosing with prophylactic dexamethasone: the BOSS program experience in myeloma
10.1016/s2152-2650(25)03484-6 · 2025
Dexamethasone for the management of CRS related to teclistamab in patients with relapsed/refractory multiple myeloma
10.1038/s41408-025-01222-y · 2025
Outpatient step-up dosing of teclistamab (TEC): an implementation process shifting from the academic inpatient (IP) to community outpatient (OP) setting
10.1016/s2152-2650(25)03481-0 · 2025
Outcomes of outpatient step-up dosing (SUD) of teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma (RRMM): findings from a large network of community practices in the USA
10.1016/s2152-2650(25)03523-2 · 2025
Tocilizumab prophylaxis for outpatient administration of teclistamab in relapsed/refractory multiple myeloma
2025
Experiences with real-world teclistamab administration in community and outpatient settings: a mixed-methods study of hematology providers
10.1080/03007995.2026.2626367 · 2026
Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM) [abstract]
2024
MM-216: Prophylactic tocilizumab to mitigate cytokine release syndrome and outpatient dosing of talquetamab in relapsed/refractory multiple myeloma: updated phase 1/2 Monumental-1 results
10.1016/s2152-2650(25)02580-7 · 2025
No additional external references are available.